Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma
Open Access
- 4 September 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8
Abstract
Cutaneous T-cell lymphoma (CTCL) comprises a group of lymphoproliferative diseases characterized by the accumulation of malignant T cells in chronically inflamed skin lesions. In early stages, the disease presents as skin patches or plaques covering a limited area of the skin and normally follows an indolent course. However, in a subset of patients the cutaneous lesions develop into tumors and the malignant T cells may spread to the lymphatic system, blood and internal organs with fatal consequences. Despite intensive research, the mechanisms driving disease progression remain incompletely understood. While most studies have focused on cancer cell-intrinsic oncogenesis, such as genetic and epigenetic events driving malignant transformation and disease progression, an increasing body of evidence shows that the interplay between malignant T cells and non-malignant cells plays a crucial role. Here, we outline some of the emerging mechanisms by which tumor, stromal and epidermal interactions may contribute to the progression of CTCL with particular emphasis on the crosstalk between fibroblasts, keratinocytes and malignant T cells.Keywords
This publication has 139 references indexed in Scilit:
- Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042Journal of Translational Medicine, 2013
- Bacterial Toxins Fuel Disease Progression in Cutaneous T-Cell LymphomaToxins, 2013
- Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)Blood, 2011
- Up-Regulation of the Chemokine CCL18 by Macrophages Is a Potential Immunomodulatory Pathway in Cutaneous T-Cell LymphomaThe American Journal of Pathology, 2011
- Infectious agents in cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2011
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2010
- Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviorsBlood, 2010
- Orchestrating the orchestrators: chemokines in control of T cell trafficNature Immunology, 2008
- Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxinsBlood, 2006
- A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoidesJournal of the American Academy of Dermatology, 2006